Embecta

Embecta Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Embecta (EMBC) as of Nov 11, 2026 is 200.94 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 45.59 % — a change of 340.72% (higher).

Cash Conversion

200.94 %

YoY

340.72%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Embecta is 2025 200.94 % . Cash Conversion Rate (OCF/Net Income) of Embecta was 2024 45.59 % . It decreases by 340.72% higher compared to the previous year.

The Embecta Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
116.90 USD
Jan 1, 2020
116.58 USD
Jan 1, 2021
109.93 USD
Jan 1, 2022
184.35 USD
Jan 1, 2023
96.16 USD
Jan 1, 2024
45.59 USD
Jan 1, 2025
200.94 USD
The Embecta Cash Conversion history
YEARCash ConversionYoY
200.94 %+340.72%
45.59 %-52.59%
96.16 %-47.83%
184.35 %+67.69%
109.93 %-5.70%
116.58 %-0.27%
116.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Cash Conversion Rate (OCF/Net Income) of Embecta is 200.94 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Embecta changed from 45.59 % to 200.94 %, representing a 340.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Embecta since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Embecta with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Embecta

All Key Metrics — Embecta